DOCSLIB.ORG

Crystal Structures of Native and Inhibitedforms of Human Cathepsin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Crystal Structures of Native and Inhibitedforms of Human Cathepsin Proc. Natl. Acad. Sci. USA Vol. 90, pp. 6796-6800, July 1993 Biochemustry Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design (aspartic protcase/N-linked oligosaccharide/pepstatin A) ERic T. BALDWIN*, T. NARAYANA BHAT*, SERGEI GULNIK*, MADHUSOODAN V. HOSUR*t, RAYMOND C. SOWDER Il, RAUL E. CACHAU*, JACK COLLINS*, ABELARDO M. SILVA*, AND JOHN W. ERICKSON*§ *Structural Biochemistry Program, Frederick Biomedical Supercomputing Center and tAIDS Vaccine Program, Program Resources Inc./DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702 Communicated by David R. Davies, March 24, 1993 (receivedfor review February 4, 1993) ABSTRACT Cathepsin D (EC 3.4.23.5) is a lysosomal duced in the vicinity of the growing tumor, may degrade the protease suspected to play important roles in protein catabo- extracellular matrix and thereby promote the escape of lism, antigen processing, degenerative diseases, and breast cancer cells to the lymphatic and circulatory systems and cancer progresson. Determination of the crystal structures of enhance the invasion of new tissues (17, 18). The design of cathepsin D and a complex with pepstatin at 2.5 A resolution potent and specific inhibitors of cathepsin D will aid the provides insights into inhibitor binding and lysosomal targeting further elucidation of the roles of this enzyme in human for this two-chain, N-glycosylated aspartic protease. Compar- disease. We previously described the purification and crys- ison with the structures of a complex of pepstatin bound to tallization ofhuman cathepsin D from liver (3); similar studies rhizopuspepsin and with a human renin-bihbitor complex have been reported recently for cathepsin D isolated from revealed differences in subsite structures and inhibitor-enzyme bovine liver (19) and human spleen (20). We now describe the interactions that are consistent with affnity differences and complete three-dimensional structure of native and pepsta- structure-activity relationships and suggest strategies for fme- tin-inhibited forms of human cathepsin D.W tuning the specificity of cathepsin D inhibitors. Mutagenesis studies have identified a phosphotransferase recognition region that is required for oligosaccharide phosphorylation but is 32 MATERIALS AND METHODS A distant from the N-domain glycosylation site at Asn-70. Crystals of native human liver cathepsin D (space group P65; Electron density for the crystal structure of cathepsin D a = b = 125.9 A, c = 104.1 A) were prepared as described (3). indicated the presence of an N-linked oligosaccharide that The structure was solved by molecular replacement using the extends from Asn-70 toward Lys-203, which is a key component program XPLOR-3.0 (21). The crystal structure of porcine of the phosphotransferase recognition region, and thus pro- pepsin was used as the search molecule (22). The final R vides a structural explanation for how the phosphotransferase factor was 18.8% for data from 10.0 to 2.5 A resolution for can recognize apparently distnt sites on the protein surface. 28,077 unique reflections. The rms deviations from ideality for bond lengths, andes, dihedral torsions, and improper Cathepsin D (EC 3.4.23.5) is an aspartic protease that is torsions were 0.012 A, 3.10, 27.30, and 1.140, respectively. normally found in the lysosomes of higher eukaryotes where Cocrystals of cathepsin D with pepstatin were prepared by it functions in protein catabolism (1). This enzyme is distin- using conditions similar to those used for the crystallization guished from other members of the pepsin family (2) by two of native enzyme. The structure of the complex was solved features that are characteristic of lysosomal hydrolases. by using the refined native structure of cathepsin D and First, mature cathepsin D is found predominantly in a two- difference Fourier methods. After a single round of refine- chain form due to a posttranslational cleavage event (1, 3). ment, the resulting 2F. - F, and F. - F, maps showed Second, it contains phosphorylated, N-linked oligosaccha- substantial electron density in the active-site region. The rides that target the enzyme to lysosomes via mannose inhibitor was built and the complex was refined to a final R 6-phosphate (M6P) receptors (4, 5). Phosphorylation in- factor of 17.9% with XPLOR. The rms deviations from ideality volves recognition of both sugar and protein structural de- for bond lengths, an.gles, dihedral torsions, and improper terminants by a phosphotransferase enzyme (6, 7). torsions were 0.012 A, 3.20, 26.60, and 1.140, respectively. Interest in cathepsin D as a target for drug design results The inhibition constants for pepstatin were determined by from its association with several biological processes of using a fluorometric assay at 370C with the substrate Ac-Glu- therapeutic significance including lysosomal biogenesis and Glu(Edans)-Lys-Pro-Ile-Cys-Phe-Phe-Arg-Leu-Gly-Lys(Dab- protein targeting (4, 5), antigen processing and the presen- cyl)-Glu-NH2, which was kindly supplied by Grant Krafft tation of peptide fragments to class II major histocompati- (Abbott) {Edans is 5-[(2-aminoethyl)amino]naphthalene-1- bility complexes (8-10), connective tissue disease pathology sulfonic acid and Dabcyl is p-(dimethylaminophenylazo)ben- (11), muscular dystrophy (12), degenerative brain changes zoic acid}. The Km for this substrate was 5 ± 0.6 ,uM and 0.3 (13, 14), and cleavage of amyloid precursor protein within ± 0.07 ,uM for cathepsin D and rhizopuspepsin, respectively. senile plaques of Alzheimer brain (15). Recent studies of In the case of cathepsin D, the inhibitor concentration was primary breast cancers demonstrated that elevated levels of cathepsin D were correlated with an increased risk of me- Abbreviations: M6P, mannose 6-phosphate; Nag, N-acetylglu- tastasis and shorter relapse-free survival (16). High levels of cosamine. cathepsin D and other proteases such as collagenase, pro- tPresent address: Solid State Physics Division, Bhabha Atomic Research Centre, Trombay, Bombay, India. §To whom reprint requests should be addressed. The publication costs ofthis article were defrayed in part by page charge 1The atomic coordinates and structure factors have been deposited payment. This article must therefore be hereby marked "advertisement" in the Protein Data Bank, Chemistry Department, Brookhaven in accordance with 18 U.S.C. §1734 solely to indicate this fact. National Laboratory, Upton NY 11973 (reference 1LYA, 1LYB). 6796 Downloaded by guest on September 24, 2021 Biochemistry: Baldwin et al. Proc. Natl. Acad. Sci. USA 90 (1993) 6797 less than or equal to the enzyme concentration, and kinetic This disulfide bridge, which had been predicted from mod- data were analyzed by using a model for tight-binding inhib- eling studies of porcine cathepsin D (26), is within the light itors (23). Michaelis-Menten kinetics were assumed with chain region and may stabilize the C terminus of the light rhizopuspepsin. The experimental data were fitted by non- chain against further proteolytic degradation. There are three linear regression analysis. proline residues in cathepsin D that refined in a cis-peptide conformation. A cis-peptide bond involving Pro-24 is con- RESULTS AND DISCUSSION served among all the aspartic proteases except for penicil- lopepsin, which has a deletion in this region. The other The 2.5 A resolution structures of native cathepsin D and of proline residues with cis-peptide bonds are localized within a its isomorphous complex with pepstatin, a naturally occur- proline-rich segment, termed the "proline loop," that con- ring aspartic protease inhibitor, were solved by molecular sists of residues Pro-312, Pro-313, cis-peptide Pro-314, Ser- replacement. The crystallographic asymmetric unit ofthe P65 315, Gly-316, and cis-peptide Pro-317. An analogous struc- unit cell contains two molecules that are identical and related ture has been described recently for human renin (24). by a pseudo-twofold rotation, K = 160.90, and by a relative Binding of pepstatin to cathepsin D induced small struc- translation of 36 A. Cathepsin D contains three topologically tural changes in the "flap" region (the (-hairpin structure distinct regions that are typical of aspartic proteases (Fig. 1): composed of residues 72-87; Fig. 1). Residues 79 and 80 at an N-terminal domain (residues 1-188), a C-terminal domain the tip of the flap moved in toward the inhibitor by about 1.7 (residues 189-346), and an interdomain, anti-parallel /3sheet A. The flexibility of this (bend decreased upon inhibitor composed of the N terminus (residues 1-7), the C terminus binding as indicated by a drop in the mean B factor from 64 (residues 330-346), and the interdomain-linking residues A2 to 25 A2 for the 16 main chain atoms of residues 78-81. (160-200). The latter region links the pseudo-twofold-related Small flap movements due to inhibitor binding have been N and C domains (K = 179.30 for the superposition of 19 Ca observed for other aspartic proteases (2). No subdomain atom pairs with a rms of 1.5 A), each ofwhich contributes an displacements were observed in cathepsin D upon inhibitor aspartic acid, Asp-33 and Asp-231, to the active site. The binding, unlike the case of pepsin (27) and endothiapepsin overall structural agreement for the main chain of cathepsin (28). D with the known structures of other mammalian aspartic The pepstatin-cathepsin D complex is stabilized by nu- proteases, human renin (24), porcine pepsin (Protein Data merous hydrogen bonds between backbone atoms of the Bank identification code, 4PEP; ref. 25), and bovine chy- inhibitor and both main chain and side chain atoms of the mosin (1CMS; ref. 25), ranged between 0.9 and 1.0 A rms. enzyme (Fig. 2A). The central statine hydroxyl group occu- Several structural features distinguish cathepsin D from pies the position of a water molecule that interacts with the other aspartic proteases.
Load more

Recommended publications
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • In Vitro Inhibition of HIV-1 Proteinase by Cerulenin
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 261, number 2, 373-377 FEBS 08165 February 1990 In vitro inhibition of HIV-1 proteinase by cerulenin Karin Moelling, Thomas Schulze, Marie-Theres Knoop, John Kay +, Raymond Jupp +, George Nicolaou* and Laurence H. Pearl* Max-Planck lnstitut fiir Molekular Genetik, lhnestrasse 73, D-IO00 Berlin 33, FRG, +Department of Biochemistry, University College of Wales, PO Box 903, Cardiff CFl 1ST, UK and *Department of Biochemistry, University College London, Gower Street, London WCIE 6BT, UK Received 13 October 1989; revised version received 18 December 1989 Retroviruses encode proteinases necessary for the proteolytic processing of the viral gag and gag-pol precursor proteins. These enzymes have been shown to be structurally and functionally related to aspartyl proteinases such as pepsin and renin. Cerulenin is a naturally occurring antibiotic, commonly used as an inhibitor of fatty acid synthesis. Cerulenin has been observed to inhibit production of Rous sarcoma virus and murine leukae- mia virus by infected cells, possibly by interfering with proteolytic processing of viral precursor proteins. We show here that cerulenin inhibits the action of the HIV-1 proteinase in vitro, using 3 substrates: a synthetic heptapeptide (SQNYPIV) which corresponds to the sequence at the HIV-I gag p17/p24 junction, a bacterially expressed gag precursor, and purified 66 kDa reverse transcriptase. Inhibition of cleavage by HIV-1 proteinase required preincubation with cerulenin. Cerulenin also inactivates endothiapepsin, a well-characterised fungal aspartyl proteinase, sug- gesting that the action of cerulenin is a function of the common active site structure of the retroviral and aspartic proteinases.
    [Show full text]
  • Functional Effects Detailed Research Plan
    GeCIP Detailed Research Plan Form Background The Genomics England Clinical Interpretation Partnership (GeCIP) brings together researchers, clinicians and trainees from both academia and the NHS to analyse, refine and make new discoveries from the data from the 100,000 Genomes Project. The aims of the partnerships are: 1. To optimise: • clinical data and sample collection • clinical reporting • data validation and interpretation. 2. To improve understanding of the implications of genomic findings and improve the accuracy and reliability of information fed back to patients. To add to knowledge of the genetic basis of disease. 3. To provide a sustainable thriving training environment. The initial wave of GeCIP domains was announced in June 2015 following a first round of applications in January 2015. On the 18th June 2015 we invited the inaugurated GeCIP domains to develop more detailed research plans working closely with Genomics England. These will be used to ensure that the plans are complimentary and add real value across the GeCIP portfolio and address the aims and objectives of the 100,000 Genomes Project. They will be shared with the MRC, Wellcome Trust, NIHR and Cancer Research UK as existing members of the GeCIP Board to give advance warning and manage funding requests to maximise the funds available to each domain. However, formal applications will then be required to be submitted to individual funders. They will allow Genomics England to plan shared core analyses and the required research and computing infrastructure to support the proposed research. They will also form the basis of assessment by the Project’s Access Review Committee, to permit access to data.
    [Show full text]
  • Features China Introduction
    Features China Introduction Tom Blundell (President, the Biochemical Society) This issue of The Biochemist is focused on biochemistry in China. It is timely because it reflects the history of biochemical research collaboration between Chinese and UK scientists, not only by looking back over the last century, but also by reviewing some of the strengths of biochemical research in China in 2011. Downloaded from http://portlandpress.com/biochemist/article-pdf/33/5/4/3914/bio033050004.pdf by guest on 27 September 2021 It has been a busy year for the Biochemical Society, which both in the UK and China. But there were interactions is celebrating its first century. It will do so at the Centenary before Needham became involved. In this issue, Randy Celebration event at the Royal Society in London in Poon draws our attention to one of these, the first paper December, but it has already done so very impressively in from China published in a journal of the Biochemical Shanghai in May with a Joint Sino–UK Protein Symposium. Society. In 1926 Ernest Tso of the Peking Union Medical There we heard about truly momentous contributions College described vitamins in preserved duck eggs, arising from interactions of influential scientists from maintaining they are “as much used on the table as is both China and UK during the last century. Just before cheese in Western countries”. the Symposium, also in May 2011, the Biochemical Journal We should also celebrate Wang Ying-Lai, who did his opened its China office in Beijing with a mini-symposium. PhD in Cambridge between 1938 and 1941.
    [Show full text]
  • Cambridge University Reporter Special Number 3
    2 OFFICERS NUMBER–MICHAELMAS TERM 2000 SPECIAL NO.3 PA RT I Chancellor: H.R.H. The Prince PHILIP, Duke of Edinburgh, T Vice-Chancellor: Prof. Sir Alec BROERS, CHU Deputy Vice-Chancellors: for –,A.M.LONSDALE, NH,O.S.O’NEILL, N,Q.R.D.SKINNER, CHR, D. E. NEWLAND, SE, Prof. D. H. MELLOR, DAR Pro-Vice-Chancellors: ,A.M.LONSDALE, NH, June , D. H. MELLOR, DAR, Dec. High Steward: Vacant Deputy High Steward: , The Rt Hon. Lord RICHARDSON, CAI Commissary: , The Rt Hon. Lord OLIVER, TH Proctors for ‒: F. H. KING, M Deputy: C. A. T. MALONE, NH R. J. STIBBS, DOW Deputy: S. A. T. REDFERN, JE Orator: ,A.J.BOWEN, JE Registrary: ,T.J.MEAD, W Deputy Registrary: ,N.J.B.A.BRANSON, DAR Secretary General of the Faculties: ,D.A.LIVESEY, EM Deputy Secretary General of the Faculties: ,G.P.ALLEN, W Librarian: ,P.K.FOX, SE Deputy Librarians: ,D.J.HALL, W , A. MURRAY, W Treasurer: ,J.M.WOMACK, TH Director of the Fitzwilliam Museum and Marlay Curator: ,D.D.ROBINSON, CL Development Director: Vacant Esquire Bedells: ,J.P.EMMINES, PET ,J.H.WILLIAMS, HH University Advocate: ,N.M.PADFIELD, F, Deputy University Advocate: ,P.J.ROGERSON, CAI, OFFICERS IN INSTITUTIONS PLACED UNDER THE SUPERVISION OF THE GENERAL BOARD PROFESSORS Aeronautical Engineering, Francis Mond W. N. D AWES, CHU Aerothermal Technology Vacant African History J. I LIFFE, JN American History, Paul Mellon A. J. BADGER, SID American History and Institutions, Pitt Vacant Anatomy W.A. HARRIS, CL Anaesthesia D. K. MENON Ancient History M.
    [Show full text]
  • Membrane Proteins • Cofactors – Plimstex • Membranes • Dna • Small Molecules/Gas • Large Complexes
    Structural mass spectrometry hydrogen/deuterium exchange Petr Man Structural Biology and Cell Signalling Institute of Microbiology, Czech Academy of Sciences Structural biology methods Low-resolution methods High-resolution methods Rigid SAXS IR Raman CD ITC MST Cryo-EM AUC SPR MS X-ray crystallography Chemical cross-linking H/D exchange Native ESI + ion mobility Oxidative labelling Small Large NMR Dynamic Structural biology approaches Simple MS, quantitative MS Cross-linking, top-down, native MS+dissociation native MS+ion mobility Cross-linking Structural MS What can we get using mass spectrometry IM – ion mobility CXL – chemical cross-linking AP – afinity purification OFP – oxidative footprinting HDX – hydrogen/deuterium exchange ISOTOPE EXCHANGE IN PROTEINS 1H 2H 3H occurence [%] 99.988 0.0115 trace 5 …Kaj Ulrik Linderstrøm-Lang „Cartesian diver“ Proteins are migrating in tubes with density gradient until they stop at the point where the densities are equal 1H 2H 3H % 99.9885 0.0115 trace density [g/cm3] 1.000 1.106 1.215 Methods of detection IR: β-: NMR: 1 n = 1.6749 × 10-27 kg MS: 1H 2H 3H výskyt% [%] 99.9885 0.0115 trace hustotadensity vody [g/cm [g/cm3] 3] 1.000 1.106 1.215 jadernýspinspin ½+ 1+ ½+ mass [u] 1.00783 2.01410 3.01605 Factors affecting H/D exchange hydrogen bonding solvent accessibility Factors affecting H/D exchange Side chains (acidity, steric shielding) Bai et al.: Proteins (1993) Glasoe, Long: J. Phys. Chem. (1960) Factors affecting H/D exchange – side chain effects Inductive effect – electron density is Downward shift due to withdrawn from peptide steric hindrance effect of bond (S, O).
    [Show full text]
  • Structure-Based Optimization of Inhibitors of the Aspartic Protease Endothiapepsin
    Int. J. Mol. Sci. 2015, 16, 19184-19194; doi:10.3390/ijms160819184 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Structure-Based Optimization of Inhibitors of the Aspartic Protease Endothiapepsin Alwin M. Hartman 1,†, Milon Mondal 1,†, Nedyalka Radeva 2, Gerhard Klebe 2 and Anna K. H. Hirsch 1,* 1 Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG Groningen, The Netherlands; E-Mails: [email protected] (A.M.H.); [email protected] (M.M.) 2 Institute of Pharmaceutical Chemistry, Philipps-University Marburg, Marbacher Weg 6, 35032 Marburg, Germany; E-Mails: [email protected] (N.R.); [email protected] (G.K.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Fax: +31-50-363-4296. Academic Editor: John George Hardy Received: 1 May 2015 / Accepted: 6 July 2015 / Published: 14 August 2015 Abstract: Aspartic proteases are a class of enzymes that play a causative role in numerous diseases such as malaria (plasmepsins), Alzheimer’s disease (β-secretase), fungal infections (secreted aspartic proteases), and hypertension (renin). We have chosen endothiapepsin as a model enzyme of this class of enzymes, for the design, preparation and biochemical evaluation of a new series of inhibitors of endothiapepsin. Here, we have optimized a hit, identified by de novo structure-based drug design (SBDD) and DCC, by using structure-based design approaches focusing on the optimization of an amide–π interaction. Biochemical results are in agreement with SBDD.
    [Show full text]
  • Progress in the Field of Aspartic Proteinases in Cheese Manufacturing
    Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering Sirma Yegin, Peter Dekker To cite this version: Sirma Yegin, Peter Dekker. Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering. Dairy Science & Technology, EDP sciences/Springer, 2013, 93 (6), pp.565-594. 10.1007/s13594-013-0137-2. hal-01201447 HAL Id: hal-01201447 https://hal.archives-ouvertes.fr/hal-01201447 Submitted on 17 Sep 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Dairy Sci. & Technol. (2013) 93:565–594 DOI 10.1007/s13594-013-0137-2 REVIEW PAPER Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering Sirma Yegin & Peter Dekker Received: 25 February 2013 /Revised: 16 May 2013 /Accepted: 21 May 2013 / Published online: 27 June 2013 # INRA and Springer-Verlag France 2013 Abstract Aspartic proteinases are an important class of proteinases which are widely used as milk-coagulating agents in industrial cheese production. They are available from a wide range of sources including mammals, plants, and microorganisms.
    [Show full text]
  • Part I Officers in Institutions Placed Under the Supervision of the General Board
    2 OFFICERS NUMBER–MICHAELMAS TERM 2009 [SPECIAL NO.7 PART I Chancellor: H.R.H. The Prince PHILIP, Duke of Edinburgh, T Vice-Chancellor: 2003, Prof. ALISON FETTES RICHARD, N, 2010 Deputy Vice-Chancellors for 2009–2010: Dame SANDRA DAWSON, SID,ATHENE DONALD, R,GORDON JOHNSON, W,STUART LAING, CC,DAVID DUNCAN ROBINSON, M,JEREMY KEITH MORRIS SANDERS, SE, SARAH LAETITIA SQUIRE, HH, the Pro-Vice-Chancellors Pro-Vice-Chancellors: 2004, ANDREW DAVID CLIFF, CHR, 31 Dec. 2009 2004, IAN MALCOLM LESLIE, CHR, 31 Dec. 2009 2008, JOHN MARTIN RALLISON, T, 30 Sept. 2011 2004, KATHARINE BRIDGET PRETTY, HO, 31 Dec. 2009 2009, STEPHEN JOHN YOUNG, EM, 31 July 2012 High Steward: 2001, Dame BRIDGET OGILVIE, G Deputy High Steward: 2009, ANNE MARY LONSDALE, NH Commissary: 2002, The Rt Hon. Lord MACKAY OF CLASHFERN, T Proctors for 2009–2010: JEREMY LLOYD CADDICK, EM LINDSAY ANNE YATES, JN Deputy Proctors for MARGARET ANN GUITE, G 2009–2010: PAUL DUNCAN BEATTIE, CC Orator: 2008, RUPERT THOMPSON, SE Registrary: 2007, JONATHAN WILLIAM NICHOLLS, EM Librarian: 2009, ANNE JARVIS, W Acting Deputy Librarian: 2009, SUSANNE MEHRER Director of the Fitzwilliam Museum and Marlay Curator: 2008, TIMOTHY FAULKNER POTTS, CL Director of Development and Alumni Relations: 2002, PETER LAWSON AGAR, SE Esquire Bedells: 2003, NICOLA HARDY, JE 2009, ROGER DERRICK GREEVES, CL University Advocate: 2004, PHILIPPA JANE ROGERSON, CAI, 2010 Deputy University Advocates: 2007, ROSAMUND ELLEN THORNTON, EM, 2010 2006, CHRISTOPHER FORBES FORSYTH, R, 2010 OFFICERS IN INSTITUTIONS PLACED UNDER THE SUPERVISION OF THE GENERAL BOARD PROFESSORS Accounting 2003 GEOFFREY MEEKS, DAR Active Tectonics 2002 JAMES ANTHONY JACKSON, Q Aeronautical Engineering, Francis Mond 1996 WILLIAM NICHOLAS DAWES, CHU Aerothermal Technology 2000 HOWARD PETER HODSON, G Algebra 2003 JAN SAXL, CAI Algebraic Geometry (2000) 2000 NICHOLAS IAN SHEPHERD-BARRON, T Algebraic Geometry (2001) 2001 PELHAM MARK HEDLEY WILSON, T American History, Paul Mellon 1992 ANTHONY JOHN BADGER, CL American History and Institutions, Pitt 2009 NANCY A.
    [Show full text]
  • Penicillopepsin-JT2, a Recombinant Enzyme from Penicillium Janthinellum and the Contribution of a Hydrogen Bond in Subsite S3 to Kcat
    Protein Science ~2000!, 9:991–1001. Cambridge University Press. Printed in the USA. Copyright © 2000 The Protein Society Penicillopepsin-JT2, a recombinant enzyme from Penicillium janthinellum and the contribution of a hydrogen bond in subsite S3 to kcat QING-NA CAO,1,3 MARLENE STUBBS,1 KENNY Q.P. NGO,1 MICHAEL WARD,2 ANNIE CUNNINGHAM,1 EMIL F. PAI,1 GUANG-CHOU TU,1,3 and THEO HOFMANN1 1 Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada 2 Genencor International, Inc., 925 Page Mill Road, Palo Alto, California 94304-1013 ~Received August 30, 1999; Final Revision February 7, 2000; Accepted March 10, 2000! Abstract The nucleotide sequence of the gene ~ pepA! of a zymogen of an aspartic proteinase from Penicillium janthinellum with a 71% identity in the deduced amino acid sequence to penicillopepsin ~which we propose to call penicillopepsin-JT1! has been determined. The gene consists of 60 codons for a putative leader sequence of 20 amino acid residues, a sequence of about 150 nucleotides that probably codes for an activation peptide and a sequence with two introns that codes for the active aspartic proteinase. This gene, inserted into the expression vector pGPT-pyrG1, was expressed in an aspartic proteinase-free strain of Aspergillus niger var. awamori in high yield as a glycosylated form of the active enzyme that we call penicillopepsin-JT2. After removal of the carbohydrate component with endoglycosidase H, its relative molecular mass is between 33,700 and 34,000. Its kinetic properties, especially the rate-enhancing effects of the presence of alanine residues in positions P3 and P29 of substrates, are similar to those of penicillopepsin-JT1, endothia- pepsin, rhizopuspepsin, and pig pepsin.
    [Show full text]
  • Iisc-Alumni Association- M.Vijayan Lecture. Cross Fertilisation: How
    IISc-Alumni Association- M.Vijayan Lecture. Cross Fertilisation: How Crystallography has built on Mathematics. Eleanor Dodson 17th August 2017 Nostalgia time: I cannot resist revisiting old photographs! Oxford 1968? Wedding Day – July 1969 DCH building first insulin model Vijayan lost in shadows? Oxford lab - 1969 Britishx5, Indian, NZ, Aust. David Phillips, Dorothy, Tony North, Thomas, Vijaya, Tom Blundell, Ted Baker, EJD Bangalore – 1970? Bangalore 1970s Kalyani, Vijayan, Tom Blundell -1975? Bangalore – 1979-80. Vijanan Davi Kalyani Bangalore 2007: Guy's 70th Birthday Cake Workshop 2008 DCH & Siv Ramasechan – 1965 our Anomalous Dispersion Guru First anomalous data measurements done in Oxford ~ 1960 on B12 derivative by K. Venkatesan Validation: More Thought Experiments: G.N. Ramachandran Mathematics in the Service of Science? Michael Mosley -BBC 2010 “Knowledge leaps forward when brilliant experiments are analysed by independent minds.” He was referring to the discovery that Mars moves in an elliptical orbit around the sun – established by Johannes Kepler -1599 using the observations of Tycho Brahe. Mathematics in the Service of Crystallography? Structure Solution exploits: Fundamental Mathematical concepts (Some elegant, but restricted to 3D for structure, and 2D for diffraction) Technical Mathematics and Computation (messy and very easy to get wrong!) Statistics (Much needed but messy too) Why crystallography? Quote: DCH: I also first learnt at the same time about biochemistry which provided me with the molecules it seemed most desirable to 'see'. …[The] great advantage of X-ray analysis as a method of chemical structure analysis is its power to show some totally unexpected and surprising structure and to do so with absolute certainty….
    [Show full text]
  • Crystal Structure of a Synthetic HIV-1 Protease
    Conserved Folding in Retroviral Proteases: Crystal Structure of a Synthetic HIV-1 Protease ALEXANDER WLODAWER, MARIA MILLER, MARIUSZ JASK6LsKi,* BANGALoRE K. SATHYANARAYANA, EIuc BALDWIN, IRENE T. WEBER, LINDA M. SELK, LEIGH CLAWSON, JENS SCHNEIDER, STEPHEN B. H. KENTt symmetric dimers with active sites resembling those in pepsin-like The rational design ofdrugs that can inhibit the action of proteases (14). However, significant differences in main chain viral proteases depends on obtaining accurate structures connectivity and secondary structure were observed between the of these enzymes. The crystal structure of chemically reported crystallographic structures ofthese two homologous retro- synthesized HIV-1 protease has been determined at 2.8 viral proteases. Particularly disturbing were the drastic differences in angstrom resolution (R factor of0.184) with the use ofa the topology of the dimer interface regions (15). model based on the Rous sarcoma virus protease struc- This puzzling disparity between the structures reported for the ture. In this enzymatically active protein, the cysteines RSV and HIV-l proteases was reinforced by a model ofHIV-1 PR were replaced by ac-amino-n-butyric acid, a nongenetically based on the crystal structure of RSV PR, proposed by Weber et al. coded amino acid. This structure, in which all 99 amino (16). The model showed that the HIV-1 PR residues could be acids were located, differs in several important details accommodated in a conformation almost identical to that of the on February 13, 2012 from that reported previously by others. The interface RSV PR. Most of the differences between the RSV PR and the between the identical subunits forming the active protease smaller HIV-1 PR molecule (124 amino acids versus 99 per dimer is composed of four well-ordered ,B strands from monomer) were limited to contiguous regions located in two both the amino and carboxyl termini and residues 86 to surface loops, and the core regions of the two structures were 94 have a helical conformation.
    [Show full text]